BUZZ-Next-generation obesity drugs in focus at upcoming diabetes meeting, Berenberg says

Reuters

Jun 11, 2025

BUZZ-Next-generation obesity drugs in focus at upcoming diabetes meeting, Berenberg says

** Berenberg analysts outline expectations for obesity drug updates during American Diabetes Association meeting on June 20-23

** Investor interest in obesity stocks waned after Novo Nordisk's NOVOb.CO CagriSema disappointed, but event could revive it with new data - Berenberg

** Adds, Eli Lilly's LLY.N orforglipron also in spotlight

** Detailed CagriSema data can highlight weight loss potential and other parameters that could help Novo move further off its lows, they say

** YTD, NOVOb is down 16.7%

** Adds, if orforglipron confirmed safe, will increase investor confidence of a 2026 launch

** Several companies to present data on amylin, and if positive, Berenberg expects a positive effect for Zealand ZELA.CO due to its high exposure

** Data on Amgen's AMGN.O MariTide, Lilly's bimagrumab and Roche's ROG.S CT-388 are also on Berenberg's radar

** It will also watch updates from BrightGene 688166.SS on BGM0504, Lilly/Innovent on mazdutide in diabetes and Terns Pharma TERN.O on oral GLP-1, TERN-601

(Reporting by Anna Pruchnicka)

((anna.pruchnicka@tr.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2542773813"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542773813\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542773813?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-11 14:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542773813","market":"us","top_or_hot":-1,"title":"BUZZ-Next-generation obesity drugs in focus at upcoming diabetes meeting, Berenberg says","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Next-generation obesity drugs in focus at upcoming diabetes meeting, Berenberg says</title></head><body><p>** Berenberg analysts outline expectations for obesity drug updates during American Diabetes Association meeting on June 20-23</p><p>** Investor interest in obesity stocks waned after Novo Nordisk's <span>NOVOb.CO</span> CagriSema disappointed, but event could revive it with new data - Berenberg</p><p>** Adds, Eli Lilly's <span>LLY.N</span> orforglipron also in spotlight </p><p>** Detailed CagriSema data can highlight weight loss potential and other parameters that could help Novo move further off its lows, they say</p><p>** <span>YTD, NOVOb is down 16.7% </span></p><p>** Adds, if orforglipron confirmed safe, will increase investor confidence of a 2026 launch</p><p>** Several companies to present data on amylin, and if positive, Berenberg expects a positive effect for Zealand <span>ZELA.CO</span> due to its high exposure</p><p>** Data on Amgen's <span>AMGN.O</span> MariTide, Lilly's bimagrumab and Roche's <span>ROG.S</span> CT-388 are also on Berenberg's radar</p><p>** It will also watch updates from BrightGene <span>688166.SS</span> on BGM0504, Lilly/Innovent on mazdutide in diabetes and Terns Pharma <span>TERN.O</span> on oral GLP-1, TERN-601</p><p> (Reporting by Anna Pruchnicka)</p><p> ((anna.pruchnicka@tr.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Next-generation obesity drugs in focus at upcoming diabetes meeting, Berenberg says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Next-generation obesity drugs in focus at upcoming diabetes meeting, Berenberg says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-11 14:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Next-generation obesity drugs in focus at upcoming diabetes meeting, Berenberg says</title></head><body><p>** Berenberg analysts outline expectations for obesity drug updates during American Diabetes Association meeting on June 20-23</p><p>** Investor interest in obesity stocks waned after Novo Nordisk's <span>NOVOb.CO</span> CagriSema disappointed, but event could revive it with new data - Berenberg</p><p>** Adds, Eli Lilly's <span>LLY.N</span> orforglipron also in spotlight </p><p>** Detailed CagriSema data can highlight weight loss potential and other parameters that could help Novo move further off its lows, they say</p><p>** <span>YTD, NOVOb is down 16.7% </span></p><p>** Adds, if orforglipron confirmed safe, will increase investor confidence of a 2026 launch</p><p>** Several companies to present data on amylin, and if positive, Berenberg expects a positive effect for Zealand <span>ZELA.CO</span> due to its high exposure</p><p>** Data on Amgen's <span>AMGN.O</span> MariTide, Lilly's bimagrumab and Roche's <span>ROG.S</span> CT-388 are also on Berenberg's radar</p><p>** It will also watch updates from BrightGene <span>688166.SS</span> on BGM0504, Lilly/Innovent on mazdutide in diabetes and Terns Pharma <span>TERN.O</span> on oral GLP-1, TERN-601</p><p> (Reporting by Anna Pruchnicka)</p><p> ((anna.pruchnicka@tr.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1548497426.USD","symbol_name":"安联环球人工智能AT Acc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nL4N3SE0E8:1","article_id":"2542773813","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542773813","pubTimestamp":1749623992,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Next-generation obesity drugs in focus at upcoming diabetes meeting, Berenberg says** Berenberg analysts outline expectations for obesity drug updates during American Diabetes Association meeting on June 20-23** Investor interest in obesity stocks waned after Novo Nordisk's NOVOb.CO CagriSema disappointed, but event could revive it with new data - Berenberg** Adds, Eli Lilly's LLY.N orforglipron also in spotlight ** Detailed CagriSema data can highlight weight loss potential and other parameters that could help Novo move further off its lows, they say** YTD, NOVOb is down 16.7% ** Adds, if orforglipron confirmed safe, will increase investor confidence of a 2026 launch** Several companies to present data on amylin, and if positive, Berenberg expects a positive effect for Zealand ZELA.CO due to its high exposure** Data on Amgen's AMGN.O MariTide, Lilly's bimagrumab and Roche's ROG.S CT-388 are also on Berenberg's radar** It will also watch updates from BrightGene 688166.SS on BGM050","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688166":"博瑞医药","LU1548497426.USD":"安联环球人工智能AT Acc","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","TERN":"Terns Pharmaceuticals, Inc.","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","AMGN":"安进","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LLY":"礼来","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","01801":"信达生物","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"贝伦贝格表示，下一代肥胖药物成为即将举行的糖尿病会议的焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688166":0.9,"AMGN":0.9,"01801":0.9,"LLY":0.9,"TERN":0.9},"content_text":"BUZZ-Next-generation obesity drugs in focus at upcoming diabetes meeting, Berenberg says** Berenberg analysts outline expectations for obesity drug updates during American Diabetes Association meeting on June 20-23** Investor interest in obesity stocks waned after Novo Nordisk's NOVOb.CO CagriSema disappointed, but event could revive it with new data - Berenberg** Adds, Eli Lilly's LLY.N orforglipron also in spotlight ** Detailed CagriSema data can highlight weight loss potential and other parameters that could help Novo move further off its lows, they say** YTD, NOVOb is down 16.7% ** Adds, if orforglipron confirmed safe, will increase investor confidence of a 2026 launch** Several companies to present data on amylin, and if positive, Berenberg expects a positive effect for Zealand ZELA.CO due to its high exposure** Data on Amgen's AMGN.O MariTide, Lilly's bimagrumab and Roche's ROG.S CT-388 are also on Berenberg's radar** It will also watch updates from BrightGene 688166.SS on BGM0504, Lilly/Innovent on mazdutide in diabetes and Terns Pharma TERN.O on oral GLP-1, TERN-601 (Reporting by Anna Pruchnicka) ((anna.pruchnicka@tr.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}